Alcohol-Related Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major alcohol-related disorders markets reached a value of US$ 667.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,628.6 Million by 2034, exhibiting a growth rate (CAGR) of 8.45% during 2024-2034.
The alcohol-related disorders market has been comprehensively analyzed in IMARC's new report titled "Alcohol-Related Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Alcohol-related disorders encompass a range of conditions that are associated with excessive and problematic alcohol use. They can have significant negative impacts on various aspects of the patient's life, including their physical health, mental well-being, social functioning, etc. Some of the common symptoms are an inability to control or limit alcohol consumption, cravings or strong urges to drink, continued usage of alcohol despite adverse consequences, withdrawal signs when attempting to cut down or quit drinking, etc. Numerous other indications may involve neglecting personal and professional responsibilities, experiencing relationship problems and social isolation, engaging in risky behaviors while under the influence, suffering from physical health issues like liver damage or neurological impairments, etc. The diagnosis of alcohol-related disorders typically involves a comprehensive assessment that considers various factors, including the patient's drinking patterns, symptoms, and the impact of alcohol use on their physical and mental health, as well as their social functioning. Healthcare professionals may utilize diagnostic criteria, such as those outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), to evaluate if the patient meets the requirements for an alcohol-related disorder.
The increasing prevalence of various associated risk factors, such as depression, anxiety, bipolar disorder, adverse childhood experiences like abuse and neglect, social and peer influences, etc., is primarily driving the alcohol-related disorders market. In addition to this, the rising incidence of genetic variations in enzymes that are involved in alcohol metabolism, neurotransmitter systems, and reward pathways, which can influence how the body processes and responds to alcohol, is creating a positive outlook for the market. Moreover, the inflating application of various medications, such as naltrexone, acamprosate, disulfiram, etc., to reduce cravings, discourage alcohol consumption, and assist in maintaining sobriety is further bolstering the market growth. Apart from this, the escalating adoption of several behavioral therapies, including cognitive-behavioral therapy (CBT), that aid patients in identifying and modifying maladaptive thoughts and behaviors related to alcohol use is acting as another significant growth-inducing factor. Additionally, the emerging popularity of relapse prevention strategies, since they help to identify triggers, manage cravings, and develop healthy coping mechanisms to prevent relapse, is expected to drive the market during the alcohol-related disorders forecast period.
IMARC Group's new report provides an exhaustive analysis of the alcohol-related disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for alcohol-related disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the alcohol-related disorders market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the alcohol-related disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the alcohol-related disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current alcohol-related disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the alcohol-related disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the alcohol-related disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the alcohol-related disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of alcohol-related disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of alcohol-related disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of alcohol-related disorders by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with alcohol-related disorders across the seven major markets?
What is the size of the alcohol-related disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of alcohol-related disorders?
What will be the growth rate of patients across the seven major markets?
Alcohol-Related Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for alcohol-related disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the alcohol-related disorders market?
What are the key regulatory events related to the alcohol-related disorders market?
What is the structure of clinical trial landscape by status related to the alcohol-related disorders market?
What is the structure of clinical trial landscape by phase related to the alcohol-related disorders market?
What is the structure of clinical trial landscape by route of administration related to the alcohol-related disorders market?
The alcohol-related disorders market has been comprehensively analyzed in IMARC's new report titled "Alcohol-Related Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Alcohol-related disorders encompass a range of conditions that are associated with excessive and problematic alcohol use. They can have significant negative impacts on various aspects of the patient's life, including their physical health, mental well-being, social functioning, etc. Some of the common symptoms are an inability to control or limit alcohol consumption, cravings or strong urges to drink, continued usage of alcohol despite adverse consequences, withdrawal signs when attempting to cut down or quit drinking, etc. Numerous other indications may involve neglecting personal and professional responsibilities, experiencing relationship problems and social isolation, engaging in risky behaviors while under the influence, suffering from physical health issues like liver damage or neurological impairments, etc. The diagnosis of alcohol-related disorders typically involves a comprehensive assessment that considers various factors, including the patient's drinking patterns, symptoms, and the impact of alcohol use on their physical and mental health, as well as their social functioning. Healthcare professionals may utilize diagnostic criteria, such as those outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), to evaluate if the patient meets the requirements for an alcohol-related disorder.
The increasing prevalence of various associated risk factors, such as depression, anxiety, bipolar disorder, adverse childhood experiences like abuse and neglect, social and peer influences, etc., is primarily driving the alcohol-related disorders market. In addition to this, the rising incidence of genetic variations in enzymes that are involved in alcohol metabolism, neurotransmitter systems, and reward pathways, which can influence how the body processes and responds to alcohol, is creating a positive outlook for the market. Moreover, the inflating application of various medications, such as naltrexone, acamprosate, disulfiram, etc., to reduce cravings, discourage alcohol consumption, and assist in maintaining sobriety is further bolstering the market growth. Apart from this, the escalating adoption of several behavioral therapies, including cognitive-behavioral therapy (CBT), that aid patients in identifying and modifying maladaptive thoughts and behaviors related to alcohol use is acting as another significant growth-inducing factor. Additionally, the emerging popularity of relapse prevention strategies, since they help to identify triggers, manage cravings, and develop healthy coping mechanisms to prevent relapse, is expected to drive the market during the alcohol-related disorders forecast period.
IMARC Group's new report provides an exhaustive analysis of the alcohol-related disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for alcohol-related disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the alcohol-related disorders market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the alcohol-related disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the alcohol-related disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current alcohol-related disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the alcohol-related disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the alcohol-related disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the alcohol-related disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of alcohol-related disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of alcohol-related disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of alcohol-related disorders by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with alcohol-related disorders across the seven major markets?
What is the size of the alcohol-related disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of alcohol-related disorders?
What will be the growth rate of patients across the seven major markets?
Alcohol-Related Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for alcohol-related disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the alcohol-related disorders market?
What are the key regulatory events related to the alcohol-related disorders market?
What is the structure of clinical trial landscape by status related to the alcohol-related disorders market?
What is the structure of clinical trial landscape by phase related to the alcohol-related disorders market?
What is the structure of clinical trial landscape by route of administration related to the alcohol-related disorders market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ALCOHOL-RELATED DISORDERS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ALCOHOL-RELATED DISORDERS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ALCOHOL-RELATED DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ALCOHOL-RELATED DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ALCOHOL-RELATED DISORDERS - UNMET NEEDS
10 ALCOHOL-RELATED DISORDERS - KEY ENDPOINTS OF TREATMENT
11 ALCOHOL-RELATED DISORDERS - MARKETED PRODUCTS
11.1 List of Alcohol-Related Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Vivitrol (Naltrexone controlled-release) - Alkermes
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Campral (Acamprosate calcium) - Forest Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 ALCOHOL-RELATED DISORDERS - PIPELINE DRUGS
12.1 List of Alcohol-Related Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 DCR-AUD - Dicerna Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Psilocybin - Clairvoyant Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 BPL-003 - Beckley Psytech Limited
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 ASP8062 - Astellas Pharma
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Arbaclofen Placarbil - Indivior Inc
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. ALCOHOL-RELATED DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ALCOHOL-RELATED DISORDERS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ALCOHOL-RELATED DISORDERS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Alcohol-Related Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Alcohol-Related Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Alcohol-Related Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Alcohol-Related Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Alcohol-Related Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Alcohol-Related Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Alcohol-Related Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Alcohol-Related Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Alcohol-Related Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Alcohol-Related Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Alcohol-Related Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Alcohol-Related Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Alcohol-Related Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Alcohol-Related Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Alcohol-Related Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Alcohol-Related Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Alcohol-Related Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Alcohol-Related Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Alcohol-Related Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Alcohol-Related Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Alcohol-Related Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Alcohol-Related Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Alcohol-Related Disorders - Access and Reimbursement Overview
16 ALCOHOL-RELATED DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ALCOHOL-RELATED DISORDERS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ALCOHOL-RELATED DISORDERS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ALCOHOL-RELATED DISORDERS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ALCOHOL-RELATED DISORDERS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ALCOHOL-RELATED DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ALCOHOL-RELATED DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ALCOHOL-RELATED DISORDERS - UNMET NEEDS
10 ALCOHOL-RELATED DISORDERS - KEY ENDPOINTS OF TREATMENT
11 ALCOHOL-RELATED DISORDERS - MARKETED PRODUCTS
11.1 List of Alcohol-Related Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Vivitrol (Naltrexone controlled-release) - Alkermes
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Campral (Acamprosate calcium) - Forest Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 ALCOHOL-RELATED DISORDERS - PIPELINE DRUGS
12.1 List of Alcohol-Related Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 DCR-AUD - Dicerna Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Psilocybin - Clairvoyant Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 BPL-003 - Beckley Psytech Limited
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 ASP8062 - Astellas Pharma
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Arbaclofen Placarbil - Indivior Inc
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. ALCOHOL-RELATED DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ALCOHOL-RELATED DISORDERS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ALCOHOL-RELATED DISORDERS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Alcohol-Related Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Alcohol-Related Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Alcohol-Related Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Alcohol-Related Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Alcohol-Related Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Alcohol-Related Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Alcohol-Related Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Alcohol-Related Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Alcohol-Related Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Alcohol-Related Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Alcohol-Related Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Alcohol-Related Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Alcohol-Related Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Alcohol-Related Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Alcohol-Related Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Alcohol-Related Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Alcohol-Related Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Alcohol-Related Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Alcohol-Related Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Alcohol-Related Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Alcohol-Related Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Alcohol-Related Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Alcohol-Related Disorders - Access and Reimbursement Overview
16 ALCOHOL-RELATED DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ALCOHOL-RELATED DISORDERS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ALCOHOL-RELATED DISORDERS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
